Dual-marker algorithm better predicts risk for ovarian cancer

Article

A novel multiple marker assay that uses serum HE4 and CA125 to calculate a risk of ovarian malignancy algorithm better predicts epithelial ovarian cancer in women with pelvic masses than the risk of malignancy index, according to recent research.

A novel multiple marker assay that uses serum HE4 and CA125 to calculate a Risk of Ovarian Malignancy Algorithm (ROMA) better predicts epithelial ovarian cancer in women with pelvic masses than the Risk of Malignancy Index (RMI), according to recently published research.

Researchers included in their study 457 women with an identified pelvic mass or ovarian cyst and planned surgical intervention. They determined RMI values using CA125, imaging score, and menopausal status and established ROMA values using HE4, CA125, and menopausal status.

The researchers found that the sensitivity for distinguishing benign masses from cancerous lesions was 94.3% for ROMA and 84.6% for RMI (P=.0029) at a set specificity of 75%. For women with stage I or II disease, sensitivities were 85.3% and 64.7%, respectively (P<.0001).

Recent Videos
March of Dimes 2024 Report highlights preterm birth crisis | Image Credit: marchofdimes.org
Understanding and managing postpartum hemorrhage: Insights from Kameelah Phillips, MD | Image Credit: callawomenshealth.com
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Christie Hilton, DO, discusses breast cancer management | Image Credit: findcare.ahn.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Related Content
© 2024 MJH Life Sciences

All rights reserved.